Topic: Pharmacogenetics and Pharmacogenomics in Human Diseases II

Pharmacogenetics and pharmacogenomics are rapidly advancing fields that aim to understand how genetic variations influence individuals' responses to drugs. These disciplines are paving the way for personalized medicine, where treatments are tailored to a patient’s genetic profile to maximize efficacy and minimize adverse effects. In Volume 2 of this Special Issue, we focus on the application of pharmacogenetics and pharmacogenomics in various human diseases, with an emphasis on translating genetic knowledge into clinical practice.

This issue will explore the latest advancements in understanding how genetic variations affect drug metabolism, efficacy, toxicity, and the underlying mechanisms of drug response. By examining diverse disease areas such as cancer, cardiovascular diseases, neurodegenerative disorders, infectious diseases, and metabolic disorders, we aim to highlight the pivotal role of pharmacogenetics in improving treatment outcomes.

Topics of interest include, but are not limited to:

● Pharmacogenomic markers in disease management: Identifying genetic variations that influence drug efficacy and safety in various diseases.

● Advancements in gene-drug interactions: Exploring how specific genetic variations alter drug metabolism and response, with examples from common and rare diseases.

● Pharmacogenomics in cancer therapy: The role of pharmacogenomic testing in optimizing cancer treatment, including chemotherapy, immunotherapy, and targeted therapies.

● Cardiovascular pharmacogenetics: Genetic factors influencing drug responses in hypertension, dyslipidemia, anticoagulation therapy, and other cardiovascular conditions.

● Neuropharmacogenomics: Genetic predictors of drug response in neurological and psychiatric conditions, such as depression, schizophrenia, and Alzheimer's disease.

● Drug toxicity and adverse drug reactions: Investigating the genetic basis of adverse reactions to medications, with a focus on rare and serious side effects.

● Novel pharmacogenetic testing platforms: Emerging technologies for pharmacogenomic testing, including next-generation sequencing and other innovative techniques, to enhance the precision and efficiency of pharmacogenetic assessments in personalized medicine.

● Ethical, legal, and social implications: Addressing the challenges of integrating pharmacogenomic data into clinical practice, including privacy, informed consent, and health equity.

● Regulatory considerations: The role of regulatory bodies in establishing guidelines for pharmacogenetic testing and its clinical integration.

We invite original research, reviews, and perspectives that advance the field of pharmacogenetics and pharmacogenomics, with a focus on their practical applications in human disease management. This Special Issue aims to promote a deeper understanding of the genetic basis of drug response, fostering the development of more effective, safe, and personalized therapeutic strategies. We look forward to receiving your submissions and advancing this critical area of research.